Unique ID issued by UMIN | UMIN000021973 |
---|---|
Receipt number | R000025329 |
Scientific Title | Multicenter prospective study on the usefulness and safety of edoxaban replacement before the endoscopic therapy with high-risk bleeding group during anticoagulant therapy with warfarin |
Date of disclosure of the study information | 2016/04/18 |
Last modified on | 2018/10/20 13:30:35 |
Multicenter prospective study on the usefulness and safety of edoxaban replacement before the endoscopic therapy with high-risk bleeding group during anticoagulant therapy with warfarin
Disestive disorders requiring the endoscopic therapy in high-risk bleeding group
Multicenter prospective study on the usefulness and safety of edoxaban replacement before the endoscopic therapy with high-risk bleeding group during anticoagulant therapy with warfarin
Disestive disorders requiring the endoscopic therapy in high-risk bleeding group
Japan |
Disestive disorders requiring the endoscopic therapy in high-risk bleeding group
Gastroenterology | Hepato-biliary-pancreatic medicine |
Malignancy
NO
To verify that usefulness and safety of the endoscopic therapy by edoxaban replacement versus heparin replacement in high-risk bleeding group from anticoagulant therapy with warfarin
Safety
Confirmatory
Pragmatic
Not applicable
The frequency of bleeding for 2 weeks after the endoscopic therapy
The frequency of thrombotic events
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Prevention
Medicine |
edoxaban replacement in high-risk bleeding group from anticoagulant therapy with warfarin.
heparin replacement in high-risk bleeding group from anticoagulant therapy with warfarin
20 | years-old | <= |
Not applicable |
Male and Female
Patients in the anticoagulation therapy with warfarin is needed the endoscopic therapy in high-risk bleeding group, and meet following criteria:
1)The patient written consent has been obtained
2)The patient over the age of 20
3) The patient's platelet 50000 / mm3 or more
1) The patient who has taken warfarin after heart valve replacement
2) The patient with severe comorbidity
3) The patient cannot be obtained with informed consent
4) The patient prohibited the participant of this study by their research investigator
180
1st name | |
Middle name | |
Last name | Shinichi Hashimoto |
Kagoshima University
Digestive and Lifestyle Diseases
8-35-1 Sakuragaoka, Kagoshima
0992755326
kumdsh@m.kufm.kagoshima-u.ac.jp
1st name | |
Middle name | |
Last name | Shinichi Hashimoto |
Kagoshima University
Digestive and Lifestyle Diseases
8-35-1 Sakuragaoka, Kagoshima
0992755326
kumdsh@m.kufm.kagoshima-u.ac.jp
Digestive and Lifestyle Diseases, Kagoshima University
Digestive and Lifestyle Diseases, Kagoshima University
Self funding
NO
2016 | Year | 04 | Month | 18 | Day |
Unpublished
Terminated
2016 | Year | 04 | Month | 18 | Day |
2016 | Year | 04 | Month | 18 | Day |
2016 | Year | 04 | Month | 18 | Day |
2018 | Year | 10 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025329
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |